Early Biomarkers for ARthritic PAIN to Guide Improved Treatments for Arthritis

Last updated: October 23, 2020
Sponsor: St George's, University of London
Overall Status: Active - Recruiting

Phase

N/A

Condition

Psoriatic Arthritis

Rheumatoid Arthritis

Ankylosing Spondylitis

Treatment

N/A

Clinical Study ID

NCT03533569
17.0192
17/LO/1894
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Osteoarthritis (OA) is a condition affecting the whole joint and is a major cause of pain and disability worldwide. Although OA is very common, the initial steps which lead to the development of pain and tissue damage are not fully understood. In this study participants will be investigated for markers in the blood, joint and urine in people who have a diagnosis of osteoarthritis or inflammatory arthritis and are receiving a steroid injection for their condition. Markers will be evaluated in participants with osteoarthritis compared with other types of arthritis, including rheumatoid arthritis and spondyloarthritis.

Eligibility Criteria

Inclusion

Inclusion Criteria: Inclusion Criteria for OA patients:

  • Fulfilling the American College of Rheumatology (ACR) criteria for the diagnosis ofknee osteoarthritis
  • Symptomatic knee pain
  • On usual care for knee osteoarthritis including paracetamol and/or NSAIDs Inclusion criteria for Inflammatory Arthritis Patients:
  • Fulfilling the American College of Rheumatology (ACR) criteria for the diagnosis ofinflammatory arthritis i.e. rheumatoid arthritis (Anti-CCP antibodies & RheumatoidFactor checked ), psoriatic arthritis or spondyloarthropathy
  • Symptomatic knee pain
  • On usual care for arthritis including disease-modifying anti-rheumatic drugs (DMARDs),paracetamol and/or NSAIDs

Exclusion

Exclusion Criteria:

  • Other rheumatological diagnosis e.g. systemic lupus erythematosus, fibromyalgia,Polymyalgia Rheumatica, Gout, Giant Cell Arteritis, Sjogren's syndrome
  • History of uncontrolled depression
  • Recent surgery
  • Uncontrolled ischaemic heart disease
  • Uncontrolled diabetes mellitus
  • Alcohol consumption > 14 units/week as per UK National guidelines
  • Participants unable to give full informed consent

Study Design

Total Participants: 150
Study Start date:
April 02, 2018
Estimated Completion Date:
April 02, 2022

Study Description

Osteoarthritis (OA) is the most common form of arthritis worldwide. OA causes major disability and pain and places a huge financial burden on healthcare worldwide. In recent work, the gene expression profile of bone marrow lesions (BML) in osteoarthritis has been evaluated. BML in OA have a novel gene expression profile which includes genes involved in inflammation, neurogenesis and matrix turnover. The plan is to investigate the functional significance of the genes found at the protein biomarker level in studies of joint tissue, blood and urine from participants with knee OA and compare these changes with participants who have other forms of arthritis, including rheumatoid arthritis and spondyloarthritis.

A study amendment was added in April 2020 due to Covid-19. We are studying up to 150 additional participants with or without inflammatory conditions who are being treated with immunomodulatory drugs compared with participants who are not on immunomodulators. We will be evaluating the course of Covid-19 infection in people without autoimmune inflammatory conditions, compared with people who have autoimmune inflammatory diseases who are on immunomodulators.

Connect with a study center

  • St George's Healthcare NHS Trust

    London, SW17 0RE
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.